Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SALWEEN study of faricimab in polypoidal choroidal vasculopathy
CTR20222310Phase 3Active
- Sponsor
- Roche
- Start
- Sep 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of faricimab in polypoidal choroidal vasculopathy (PCV), sponsored by Roche. Started Sep 2023; status: active.
02
Drugs
faricimab
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on CTR20222310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222310.